English EN Spanish ES French FR Chinese (Simplified) ZH-CN

Lymphoma

Lymphoma

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

60 Clinical Trials
Lymphoma NA Active
nct/study# NCT04981795 / MOR208C414

Prospective Multicenter Observational Study Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Starting Second- Or Third-Line Therapy And Not Receiving Autologous Stem Cell Transplant (REAL-MIND)

Learn More
Lymphoma Phase I Accepting Patients
nct/study# NCT04231747 / CC-97540-NHL-001

A Phase 1, Multicenter, Open-Label Study Of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT03646123 / SGN35-027

Multiple Part Clinical Trial Of Brentuximab Vedotin In Classical Hodgkin Lymphoma Subjects

Learn More
Lymphoma Phase I Accepting Patients
nct/study# NCT03930953 / CC-99282-NHL-001

A Phase 1, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, CC-99282, Alone And In Combination With Rituximab In Subjects With Relapsed Or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Learn More
Lymphoma NA Accepting Patients
nct/study# NA / 2021-0513

Outcomes Of Patients With Aggressive B-Cell Non-Hodgkin S Lymphoma Who Undergo Hematopoietic Cell Transplantation After CAR T-Cell Therapy

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT03113500 / COH-17058

A Phase 2 Study Of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, And Prednisone (CHEP-BV) Followed By BV Consolidation In Patients With CD30-Positive Peripheral T-Cell Lymphomas

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.